ID

44396

Descrizione

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00866047

collegamento

https://clinicaltrials.gov/show/NCT00866047

Keywords

versioni (2)
  1. 04/06/18 04/06/18 -
  2. 20/09/21 20/09/21 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

20 settembre 2021

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Lymphoma, Large-Cell, Anaplastic NCT00866047

Inglese

Eligibility Lymphoma, Large-Cell, Anaplastic NCT00866047

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with relapsed or refractory systemic alcl who have previously received front line chemotherapy.
Descrizione

Systemic Anaplastic Large Cell Lymphoma Relapsed | Systemic Anaplastic Large Cell Lymphoma refractory | Status post Chemotherapeutics regimen first line of treatment

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1336548
UMLS CUI [1,2]
C0205336
UMLS CUI [2,1]
C1336548
UMLS CUI [2,2]
C0205269
UMLS CUI [3,1]
C0231290
UMLS CUI [3,2]
C2045825
documented anaplastic lymphoma kinase (alk) status.
Descrizione

Anaplastic lymphoma kinase Status Documented

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0252409
UMLS CUI [1,2]
C0449438
UMLS CUI [1,3]
C1301725
histologically-confirmed cd30-positive disease; tissue from the most recent post diagnostic biopsy of relapsed/refractory disease must be available for confirmation of cd30 expression via slides or tumor block.
Descrizione

Disease CD30 positive | Tissue specimen Biopsy Recurrent disease | Tissue specimen Biopsy Refractory Disease | CD30 expression Slide | CD30 expression Tumor Block

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C3888910
UMLS CUI [2,1]
C1292533
UMLS CUI [2,2]
C0005558
UMLS CUI [2,3]
C0277556
UMLS CUI [3,1]
C1292533
UMLS CUI [3,2]
C0005558
UMLS CUI [3,3]
C1514815
UMLS CUI [4,1]
C3888510
UMLS CUI [4,2]
C1705201
UMLS CUI [5,1]
C3888510
UMLS CUI [5,2]
C0027651
UMLS CUI [5,3]
C1533157
fluorodeoxyglucose-avid and measurable disease of at least 1.5 cm as documented by both positron emission tomography and spiral computed tomography.
Descrizione

Fluorodeoxyglucose F18 Avidity PET | Measurable Disease Size PET | Fluorodeoxyglucose F18 Avidity Spiral CT | Measurable Disease Size Spiral CT

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0046056
UMLS CUI [1,2]
C1510996
UMLS CUI [1,3]
C0032743
UMLS CUI [2,1]
C1513041
UMLS CUI [2,2]
C0456389
UMLS CUI [2,3]
C0032743
UMLS CUI [3,1]
C0046056
UMLS CUI [3,2]
C1510996
UMLS CUI [3,3]
C0860888
UMLS CUI [4,1]
C1513041
UMLS CUI [4,2]
C0456389
UMLS CUI [4,3]
C0860888
received any previous autologous stem cell transplant at least 12 weeks (3 months) prior.
Descrizione

Autologous hematopoietic stem cell transplant

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2193200
at us sites, patients greater than or equal to 12 years of age may be enrolled. at non-us sites, patients must be greater than or equal to 18 years of age.
Descrizione

Age | Geographic Location

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0017446
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous treatment with brentuximab vedotin.
Descrizione

brentuximab vedotin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2973446
previously received an allogeneic transplant.
Descrizione

Transplantation, Homologous

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0040739
patients with current diagnosis of primary cutaneous alcl (patients who have transformed to systemic alcl are eligible).
Descrizione

Primary Cutaneous Anaplastic Large Cell Lymphoma | Patients Transformed Systemic Anaplastic Large Cell Lymphoma Eligible

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1301362
UMLS CUI [2,1]
C0030705
UMLS CUI [2,2]
C0457344
UMLS CUI [2,3]
C1336548
UMLS CUI [2,4]
C1548635
known cerebral/meningeal disease.
Descrizione

Cerebral disorder | Meningeal disorder

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0234387
UMLS CUI [2]
C0154728
Ritorna all'inizio della pagina

Similar models

Eligibility Lymphoma, Large-Cell, Anaplastic NCT00866047

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Systemic Anaplastic Large Cell Lymphoma Relapsed | Systemic Anaplastic Large Cell Lymphoma refractory | Status post Chemotherapeutics regimen first line of treatment
Item
patients with relapsed or refractory systemic alcl who have previously received front line chemotherapy.
boolean
C1336548 (UMLS CUI [1,1])
C0205336 (UMLS CUI [1,2])
C1336548 (UMLS CUI [2,1])
C0205269 (UMLS CUI [2,2])
C0231290 (UMLS CUI [3,1])
C2045825 (UMLS CUI [3,2])
Anaplastic lymphoma kinase Status Documented
Item
documented anaplastic lymphoma kinase (alk) status.
boolean
C0252409 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
C1301725 (UMLS CUI [1,3])
Disease CD30 positive | Tissue specimen Biopsy Recurrent disease | Tissue specimen Biopsy Refractory Disease | CD30 expression Slide | CD30 expression Tumor Block
Item
histologically-confirmed cd30-positive disease; tissue from the most recent post diagnostic biopsy of relapsed/refractory disease must be available for confirmation of cd30 expression via slides or tumor block.
boolean
C0012634 (UMLS CUI [1,1])
C3888910 (UMLS CUI [1,2])
C1292533 (UMLS CUI [2,1])
C0005558 (UMLS CUI [2,2])
C0277556 (UMLS CUI [2,3])
C1292533 (UMLS CUI [3,1])
C0005558 (UMLS CUI [3,2])
C1514815 (UMLS CUI [3,3])
C3888510 (UMLS CUI [4,1])
C1705201 (UMLS CUI [4,2])
C3888510 (UMLS CUI [5,1])
C0027651 (UMLS CUI [5,2])
C1533157 (UMLS CUI [5,3])
Fluorodeoxyglucose F18 Avidity PET | Measurable Disease Size PET | Fluorodeoxyglucose F18 Avidity Spiral CT | Measurable Disease Size Spiral CT
Item
fluorodeoxyglucose-avid and measurable disease of at least 1.5 cm as documented by both positron emission tomography and spiral computed tomography.
boolean
C0046056 (UMLS CUI [1,1])
C1510996 (UMLS CUI [1,2])
C0032743 (UMLS CUI [1,3])
C1513041 (UMLS CUI [2,1])
C0456389 (UMLS CUI [2,2])
C0032743 (UMLS CUI [2,3])
C0046056 (UMLS CUI [3,1])
C1510996 (UMLS CUI [3,2])
C0860888 (UMLS CUI [3,3])
C1513041 (UMLS CUI [4,1])
C0456389 (UMLS CUI [4,2])
C0860888 (UMLS CUI [4,3])
Autologous hematopoietic stem cell transplant
Item
received any previous autologous stem cell transplant at least 12 weeks (3 months) prior.
boolean
C2193200 (UMLS CUI [1])
Age | Geographic Location
Item
at us sites, patients greater than or equal to 12 years of age may be enrolled. at non-us sites, patients must be greater than or equal to 18 years of age.
boolean
C0001779 (UMLS CUI [1])
C0017446 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
brentuximab vedotin
Item
previous treatment with brentuximab vedotin.
boolean
C2973446 (UMLS CUI [1])
Transplantation, Homologous
Item
previously received an allogeneic transplant.
boolean
C0040739 (UMLS CUI [1])
Primary Cutaneous Anaplastic Large Cell Lymphoma | Patients Transformed Systemic Anaplastic Large Cell Lymphoma Eligible
Item
patients with current diagnosis of primary cutaneous alcl (patients who have transformed to systemic alcl are eligible).
boolean
C1301362 (UMLS CUI [1])
C0030705 (UMLS CUI [2,1])
C0457344 (UMLS CUI [2,2])
C1336548 (UMLS CUI [2,3])
C1548635 (UMLS CUI [2,4])
Cerebral disorder | Meningeal disorder
Item
known cerebral/meningeal disease.
boolean
C0234387 (UMLS CUI [1])
C0154728 (UMLS CUI [2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial